Delivery Order SPE2DB22D1106-SPE2DB24FEVC5
Award Date
6/3/24
Potential Completion Date
6/4/24
Potential Value
$34K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $53,731.77, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product, with a completion date of July 3, 2024. The contract is a Firm Fixed Price Delivery Order, without any set-aside designation. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract...
This federal contract award, valued at $100,378.46, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a medical product, with an ultimate completion date of January 7, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop...
This federal contract award, valued at $11,536.35, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has an ultimate completion date of March 4, 2024 and is a Firm Fixed Price Delivery Order. The contract was not set aside for any specific business type. AmerisourceBergen Drug Corp holds a...
This federal contract award, valued at $11,566.45, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a medical product, with a completion date of November 13, 2024. The contract is a Delivery Order, with a Firm Fixed Price pricing type, and does not have a set-aside designation. AmerisourceBergen Drug Corp holds a significant...
This federal contract award, valued at $22,363.12, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a medical product, with a completion date of May 15, 2024. The contract is a delivery order with a firm fixed price pricing type, and it is not associated with a set-aside designation. AmerisourceBergen holds a significant...
This federal contract award, valued at $10,834.76, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product, with a completion date of January 24, 2025. The contract has a Firm Fixed Price pricing type and does not have a set-aside designation, indicating open competition. Additionally,...
This federal contract award is a delivery order valued at $9,654.66 with an ultimate completion date of March 21, 2025. The award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a medical product. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed price delivery order contract worth $38,700.68 to AmerisourceBergen Drug Corporation's Corporate Office Division. The contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has an ultimate completion date of August 12, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999 and running through December 2025,...
This federal contract award, valued at $24,473.36, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty pharmaceutical product. The contract has no set-aside designation, indicating open competition. It is a Delivery Order contract with a Firm Fixed Price pricing type, with an ultimate completion date of March 10, 2025....
This federal contract award is a Delivery Order from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $70,949.25, is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has a Firm Fixed Price pricing type and an ultimate completion date of December 14, 2023. The contract is not designated with a set-aside requirement, indicating open competition....